Search

Start Over Subjects Hypercholesterolemia -- drug therapy

1. Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial

Author(s):
Asch, David A., author
Troxel, Andrea B., author
Stewart, Walter F., author
Sequist, Thomas D., author
Jones, James B., author
Hirsch, AnneMarie G., author
Hoffer, Karen, author
Zhu, Jingsan, author
Wang, Wenli, author
Hodolfski, Amanda, author
Frasch, Antoinette B., author
Weiner, Mark G., author
Finnerty, Darra D., author
Rosenthal, Meredith B., author
Gangemi, Kelsey, author
Volpp, Kevin G., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Subject(s):
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors -- therapeutic use
Hypercholesterolemia -- drug therapy
Medication Adherence
Motivation
Reimbursement, Incentive
Goals
Physicians, Family
Randomized Controlled Trials as Topic
Humans
United States

2. Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers

Author(s):
Doshi, Jalpa A., author
Puckett, Justin T., author
Parmacek, Michael S., author
Rader, Daniel J., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Eligibility Determination
Insurance Coverage
Insurance, Health
Proprotein Convertase 9 -- antagonists & inhibitors
Serine Proteinase Inhibitors -- economics
Serine Proteinase Inhibitors -- therapeutic use
Economics, Pharmaceutical
Formularies as Topic
Hypercholesterolemia -- drug therapy
Medicaid -- economics
Medicare -- economics
Private Sector
Public Sector
Humans
Pennsylvania
United States